tiprankstipranks
MoonLake Immunotherapeutics (MLTX)
NASDAQ:MLTX
US Market

MoonLake Immunotherapeutics (MLTX) Income Statement

Compare
319 Followers

MoonLake Immunotherapeutics Income Statement

Last quarter (Q3 2024), MoonLake Immunotherapeutics's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q3, MoonLake Immunotherapeutics's net income was $-35.39M. See MoonLake Immunotherapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit
$ -13.16K$ -12.36K$ -4.97K$ 0.00
Operating Expenses
$ 54.12M$ 65.06M$ 53.57M$ 105.75K
Depreciation and Amortization
$ 13.16K$ 12.36K$ 4.97K$ 206.30K
EBITDA
$ -54.11M$ -65.05M$ -53.63M$ -90.84K
Operating Income
$ -54.12M$ -65.06M$ -53.58M$ -105.76K
Other Income/Expenses
$ 10.14M$ 591.73K$ 10.65M$ 14.92K
Pretax Income
$ -43.98M$ -64.47M$ -53.64M$ -90.84K
Net Income
$ -36.01M$ -64.51M$ -53.64M$ -90.84K
Per Share Metrics
$ ―$ ―$ ―$ ―
Basic EPS
$ -0.73$ -2.20$ -6.84$ -0.01
Diluted EPS
$ -0.73$ -2.20$ -6.84$ -0.01
Weighted Average Shares Outstanding
49.12M 29.36M 7.84M 14.80M
Weighted Average Shares Outstanding (Diluted)
49.12M 29.36M 7.84M 14.80M
Currency in USD

MoonLake Immunotherapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis